Page last updated: 2024-10-29

avapro and Chronic Disease

avapro has been researched along with Chronic Disease in 16 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels."6.70Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001)
"Patients treated with amiodarone plus irbesartan had a lower rate of recurrence of atrial fibrillation than did patients treated with amiodarone alone."5.10Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. ( Bernal, E; Bueno, MG; Cabeza, P; Cano, JM; Cano, L; Madrid, AH; Marín, I; Moro, C; Peña, G; Rebollo, JM; Rodriguez, A, 2002)
"In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors."5.09Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. ( Bianchetti, MG; Teuffel, O; von Vigier, RO; Zberg, PM, 2000)
" In group A, 8 weeks of treatment induced a two- to nine-fold reduction in urinary cytokine levels (GCSF, GM-CSF, IFN-γ, IL-1a, IL-11, IL-12p40, MCP-2, MIP-1a), while increasing the dosage to 300 mg/d further decreased the excretion of GCSF, GM-CSF, IL-12p40, MCP-2 and MIP-1a by week 18."2.77Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease. ( Huang, HQ; Liu, BC; Lü, LL; Ni, J; Zheng, M, 2012)
"Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels."2.70Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's10 (62.50)29.6817
2010's3 (18.75)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Liu, Z1
Zhang, L1
Zhai, R1
Lan, J1
Nijiati, Y1
Yang, T1
Aimaiti, M1
Maimaitiyiming, D1
Aikemu, A1
Desai, RJ1
Ashton, CM1
Deswal, A1
Morgan, RO1
Mehta, HB1
Chen, H1
Aparasu, RR1
Johnson, ML1
Ni, J1
Huang, HQ1
Lü, LL1
Zheng, M1
Liu, BC1
Tsuruoka, S1
Kai, H1
Usui, J1
Morito, N1
Saito, C1
Yoh, K1
Yamagata, K1
Madrid, AH1
Bueno, MG1
Rebollo, JM1
Marín, I1
Peña, G1
Bernal, E1
Rodriguez, A1
Cano, L1
Cano, JM1
Cabeza, P1
Moro, C1
Haneda, M1
Lods, N1
Ferrari, P1
Frey, FJ1
Kappeler, A1
Berthier, C1
Vogt, B1
Marti, HP1
Falcão, LM1
Pinto, F1
Ravara, L1
van Zwieten, PA1
Höcht, C1
Opezzo, JA1
Taira, CA1
Tu, X1
Chen, X1
Xie, Y1
Shi, S1
Wang, J1
Chen, Y1
Li, J1
Willenheimer, R1
von Vigier, RO1
Zberg, PM1
Teuffel, O1
Bianchetti, MG1
Upnitskiĭ, AA1
Khanina, NIu1
Belousov, IuB1
McDonald, JE1
Padmanabhan, N1
Petrie, MC1
Hillier, C1
Connell, JM1
McMurray, JJ1
Würzner, G1
Gerster, JC1
Chiolero, A1
Maillard, M1
Fallab-Stubi, CL1
Brunner, HR1
Burnier, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190]Phase 30 participants (Actual)Interventional2017-12-02Withdrawn (stopped due to Investigational Medicinal Product Supplies)
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397]Phase 440 participants (Anticipated)Interventional2022-07-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for avapro and Chronic Disease

ArticleYear
[Diabetic nephropathy].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers;

2002

Trials

8 trials available for avapro and Chronic Disease

ArticleYear
Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.
    Chinese medical journal, 2012, Volume: 125, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Creatinine; Cross-Over

2012
Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3

    Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Biphe

2013
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
    Circulation, 2002, Jul-16, Volume: 106, Issue:3

    Topics: Adult; Aged; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2002
Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.
    Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:11

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl C

2003
BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2004, Volume: 5, Issue:3

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Natr

2004
Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    European journal of pediatrics, 2000, Volume: 159, Issue:8

    Topics: Adolescent; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2000
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
    Circulation, 2001, Oct-09, Volume: 104, Issue:15

    Topics: Administration, Oral; Angina Pectoris; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonis

2001
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
    Journal of hypertension, 2001, Volume: 19, Issue:10

    Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind

2001

Other Studies

7 other studies available for avapro and Chronic Disease

ArticleYear
Comparison of Irbesartan and Benazepril Hydrochloride on Urine Protein Reduction in Chronic Glomerulonephritis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:9

    Topics: Benzazepines; Chronic Disease; Glomerulonephritis; Humans; Irbesartan

2020
Irbesartan ameliorates chronic mountain sickness in a rat model via the cholesterol metabolism: An iTRAQ -based proteomics analysis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 141

    Topics: Altitude Sickness; Animals; Antihypertensive Agents; Cholesterol; Chronic Disease; Irbesartan; Prote

2021
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confoun

2012
Hypothalamic antihypertensive effect of irbesartan in chronic aortic coarctated rats.
    Pharmacology, 2005, Volume: 73, Issue:3

    Topics: Animals; Antihypertensive Agents; Aortic Coarctation; Biphenyl Compounds; Chronic Disease; Female; H

2005
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
    Journal of the American Society of Nephrology : JASN, 2008, Volume: 19, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood

2008
Comment on "Effects of long-term angiotensin II AT-1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats".
    Cardiovascular research, 1999, Aug-01, Volume: 43, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun

1999
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].
    Klinicheskaia meditsina, 2001, Volume: 79, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Dose-Response Relatio

2001